Key result
PDGFRA amplification linked to ~190% higher mortality after chemotherapy initiation in advanced undifferentiated pleomorphic sarcoma.
Why the study?
The genomic landscape of advanced undifferentiated pleomorphic sarcoma (UPS) has been analyzed in small numbers, and the relationship between gene variants and prognosis remains unclear.
Does PDGFRA amplification affect survival in patients with advanced undifferentiated pleomorphic sarcoma?
Population
233 patients with advanced UPS in Japan, median age 60.2 years, 151 men (64.8%)
Comparison
Patients with PDGFRA amplification vs without PDGFRA amplification
Design
Retrospective cohort study using comprehensive genomic profiling from C-CAT database
Authors
Loading...
May stratify prognosis in advanced UPS; leaves open PDGFRA inhibition as a therapeutic target.
Cohort (n=233)
Does PDGFRA amplification affect survival in patients with advanced undifferentiated pleomorphic sarcoma?
Hazard Ratio: 2.9 (95% CI 1.2–6.9)
p-value: p=0.02
PDGFRA amplification is a poor prognostic factor for survival in patients with advanced undifferentiated pleomorphic sarcoma.
Kobayashi et al. (2026) conducted a cohort in Advanced undifferentiated pleomorphic sarcoma (n=233). PDGFRA amplification vs. Without PDGFRA amplification was evaluated on Survival from the initiation of chemotherapy (HR 2.9, 95% CI 1.2-6.9, p=0.02). PDGFRA amplification was associated with worse survival from the initiation of chemotherapy in patients with advanced undifferentiated pleomorphic sarcoma (HR 2.9; 95% CI 1.2-6.9; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: